![Bing Yao](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bing Yao
Directeur Général chez
ARRIVENT BIOPHARMA, INC.
Fortune : 19 M $ au 31/08/2026
Profil
Zheng Bin Yao is the founder of Arrivent BioPharma, Inc., founded in 2021, serving as Chairman & Chief Executive Officer.
Current jobs include Director at Immune-Onc Therapeutics, Inc. since 2019, Independent Director at Alumis, Inc. since 2021, and Director at NiKang Therapeutics, Inc. Former jobs include Chairman, President & Chief Executive Officer at Viela Bio, Inc. from 2019 to 2021; Independent Director at NexImmune, Inc. from 2017 to 2024; Independent Non-Executive Director at VISEN Pharmaceuticals from 2021 to 2026; Senior Vice President & Head-Immuno-Oncology at MedImmune LLC from 2015 to 2018; Head-Immuno-Oncology Franchise at AstraZeneca PLC; Head-Immunology & Infectious Diseases at Genentech, Inc.; and Vice President & Head-Research at Tanox, Inc. from 2000 to 2007.
Education includes a doctorate from the University of Iowa and graduate studies at Anhui Medical University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC. 1,32 % | 21/04/2026 | 613 138 ( 1,32 % ) | 18 M $ | 31/08/2026 |
ALUMIS INC. 0,02 % | 30/06/2026 | 27 082 ( 0,02 % ) | 590 658 $ | 31/08/2026 |
Postes actifs de Bing Yao
| Sociétés | Poste | Début |
|---|---|---|
| ALUMIS INC. | Directeur/Membre du Conseil | 01/06/2021 |
| ARRIVENT BIOPHARMA, INC. | Directeur Général | 01/06/2021 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Directeur/Membre du Conseil | 01/04/2019 |
NiKang Therapeutics, Inc.
 NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Directeur/Membre du Conseil | - |
Anciens postes connus de Bing Yao
| Sociétés | Poste | Fin |
|---|---|---|
| VISEN PHARMACEUTICALS | Directeur/Membre du Conseil | 27/08/2026 |
| NEXIMMUNE, INC. | Directeur/Membre du Conseil | 27/08/2024 |
| VIELA BIO, INC. | Directeur Général | 15/03/2021 |
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | 01/02/2018 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Corporate Officer/Principal | 19/10/2007 |
Formation de Bing Yao
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
60
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Health Technology |
NexImmune, Inc.
 NexImmune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that develops T cell immunotherapies | Health Technology |
University of Iowa
 University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anhui Medical University
 Anhui Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company that develops treatments for inflammation and autoimmune diseases | Health Technology |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Health Technology |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Engages in research and development of medicines for autoimmune disorders | Health Technology |
Arrivent BioPharma, Inc.
 Arrivent BioPharma, Inc. Pharmaceuticals: OtherHealth Technology Engages in development and commercialization of cancer medicines | Health Technology |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
